Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
Ticker SymbolHSDT
Company nameHelius Medical Technologies Inc
IPO dateJun 27, 2014
CEOMr. Dane C. Andreeff
Number of employees21
Security typeOrdinary Share
Fiscal year-endJun 27
Address642 Newtown Yardley Road
CityNEWTOWN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code18940
Phone12159446100
Websitehttps://heliusmedical.com/
Ticker SymbolHSDT
IPO dateJun 27, 2014
CEOMr. Dane C. Andreeff
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data